Publications & Posters
Scholary publications
Immuno-Oncology
SRK-181
January 2021
2021 TGFβ for Immuno-Oncology Drug Development Summit
Inhibition of TGFβ1 Activation with SRK-181 Overcomes Primary Resistance to Checkpoint Inhibition Therapy
Immuno-Oncology
SRK-181
November 2020
Society for Immunotherapy of Cancer's (SITC) Annual Meeting
DRAGON: Phase 1 trial of SRK-181, a latent TGFβ1 inhibitor, in combination with anti-PD-(L)1 inhibitors for patients with solid tumors unresponsive to anti-PD-(L)1 therapy alone
Spinal Muscular Atrophy
Apitegromab
September 2020
World Muscle Society
Myostatin Dynamics in Health and Disease: Pharmacologic Effects of SRK-015, a Highly Selective Monoclonal Antibody Inhibitor of Myostatin Activation
Spinal Muscular Atrophy
Apitegromab
September 2020
World Muscle Society
Clinical Development of SRK-015,a Fully Human Anti-proMyostatin Monoclonal Antibody, for the Treatment of Later-Onset Spinal Muscular Atrophy
Spinal Muscular Atrophy
Apitegromab
June 2020
CURE SMA Annual Conference
Clinical Development of SRK-015 for the Treatment of Later-Onset Spinal Muscular Atrophy
Spinal Muscular Atrophy
Apitegromab
June 2020
CURE SMA Annual Conference
